The Supriya Lifescience IPO allotment, which took place from December 16, 2021, to December 20, 2021, was a significant event in the financial market. This IPO was a book-built issue with a total value of ₹700.00 crores, comprising a fresh issue of ₹200.00 crores and an offer for sale of ₹500.00 crores. The price band was set at ₹265 to ₹274 per share, with a minimum lot size of 54 shares, requiring retail investors to make a minimum investment of ₹14,796. The allotment was finalized on December 23, 2021, and the shares were listed on the BSE and NSE on December 28, 2021. Qualified Institutional Buyers (QIB) received 54.55% of the shares, Non-Institutional Investors (NII) received 27.27%, and Retail Individual Investors (RII) received 18.18%.
Key Points of Supriya Lifescience IPO Allotment
What is the Supriya Lifescience IPO?
The Supriya Lifescience IPO was an opportunity for investors to buy shares in Supriya Lifescience Limited. The IPO was open for subscription from December 16 to December 20, 2021.
Which Investor Categories Participated?
- Qualified Institutional Buyers (QIB): Received 54.55% of the shares.
- Non-Institutional Investors (NII): Received 27.27%.
- Retail Individual Investors (RII): Received 18.18%.
When and Where Did the Supriya Lifescience IPO Allotment and Listing Occur?
- Allotment Finalization: December 23, 2021.
- Listing Date: December 28, 2021.
- Listing Exchanges: Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).
Price Band and Minimum Investment Of Supriya Lifescience IPO Allotment
- Price Band: ₹265 to ₹274 per share.
- Minimum Lot Size: 54 shares.
- Minimum Investment for Retail Investors: ₹14,796.
Detailed Explanation of Supriya Lifescience IPO Allotment
What: The Supriya Lifescience IPO Allotment
The Supriya Lifescience IPO allowed investors to participate in the growth story of Supriya Lifescience Limited. The IPO was structured as a book-built issue, meaning that the final issue price was determined after receiving bids from investors.
Which: Investor Categories and Their Allocations
Qualified Institutional Buyers (QIBs): These large institutional investors, including mutual funds, foreign portfolio investors, and banks, received the majority of the shares. QIBs were allocated 54.55% of the total issue.
Non-Institutional Investors (NIIs): High-net-worth individuals and companies fell under this category. They received 27.27% of the total shares offered.
Retail Individual Investors (RIIs): Retail investors, typically small individual investors, were allocated 18.18% of the shares. The minimum investment required for retail investors was ₹14,796.
When: Key Dates for the Supriya Lifescience IPO
- IPO Open Date: December 16, 2021
- IPO Close Date: December 20, 2021
- Basis of Allotment: December 23, 2021
- Refunds Initiated: December 24, 2021
- Shares Credited to Demat Accounts: December 27, 2021
- Listing Date: December 28, 2021
Where: Stock Exchanges for Listing for Supriya Lifescience IPO Allotment
The shares of Supriya Lifescience were listed on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
How: Allotment and Listing Process of Supriya Lifescience IPO Allotment
The allotment process involved finalizing the list of investors who would receive shares. This was completed on December 23, 2021. Once the allotment was finalized, the refunds for unsuccessful bids were initiated on December 24, 2021. The shares were credited to the investors’ demat accounts on December 27, 2021, and the company was officially listed on BSE and NSE on December 28, 2021.
Important Aspects to Consider For Supriya Lifescience IPO Allotment
Why Participate in the Supriya Lifescience IPO?
Investing in the Supriya Lifescience IPO was seen as an opportunity to be part of a growing pharmaceutical company with a promising future. However, as with any investment, it was important to understand the company’s financial health, market position, and potential risks.
Number of Shares and Allotment Criteria
In the case of oversubscription, the shares were allotted on a proportional basis within each investor category, ensuring fair distribution.
Risks and Considerations Of Supriya Lifescience IPO Allotment
While the Supriya Lifescience IPO offered a chance to invest in a potentially lucrative venture, it was essential to recognize the inherent risks of IPO investments. Market volatility, company performance, and economic factors could all impact the returns on investment.
Final Thoughts on Supriya Lifescience IPO Allotment
The Supriya Lifescience IPO was a significant event in the financial market, attracting various types of investors. The process, from subscription to listing, was handled efficiently, providing a structured opportunity for investment.
For those interested in creating a demat account to participate in future IPOs and stock market investments, click the button below:
GRM Bulls provides comprehensive financial services and assistance. If you want to learn trading, visit our platform at GRM IIT.
Summary Table of Key Details Of Supriya Lifescience IPO Allotment
| Detail | Information |
|---|---|
| IPO Open Date | December 16, 2021 |
| IPO Close Date | December 20, 2021 |
| Price Band | ₹265 to ₹274 per share |
| Minimum Lot Size | 54 shares |
| Minimum Investment | ₹14,796 |
| Allotment Finalization | December 23, 2021 |
| Refunds Initiated | December 24, 2021 |
| Shares Credited | December 27, 2021 |
| Listing Date | December 28, 2021 |
| QIB Allocation | 54.55% |
| NII Allocation | 27.27% |
| RII Allocation | 18.18% |
Understanding the details of the Supriya Lifescience IPO allotment helps investors make informed decisions. Whether you are a qualified institutional buyer, non-institutional investor, or retail individual investor, knowing the key aspects of the IPO process is crucial.
Investing in IPOs can be rewarding, but it requires careful consideration and understanding of the market dynamics. Always conduct thorough research and consider seeking advice from financial experts before making investment decisions.